XML 40 R31.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

9 Months Ended

Sep. 30, 2023

Segment Information

Summary of results of operations by segment


(In thousands)					Contract			Corporate			Total
Three Months Ended September 30, 2023		Therapeutics			Research			and Other			Company
Total revenue		$	8,577		$	4,817		$	(4,112)		$	9,282
Cost of revenue			—			4,726			(3,878)			848
Research and development			24,110			—			(234)			23,876
General and administrative			—			1,174			5,917			7,091
Licensing			7,344			—			—			7,344
Revaluation of contingent consideration			1,700			—			—			1,700
Loss from operations		$	(24,577)		$	(1,083)		$	(5,917)		$	(31,577)

(In thousands)					Contract			Corporate			Total
Three Months Ended September 30, 2022		Therapeutics			Research			and Other			Company
Total revenue		$	17,928		$	4,299		$	(3,209)		$	19,018
Cost of revenue			—			3,925			(3,002)			923
Research and development			23,863			—			(207)			23,656
General and administrative			—			875			4,938			5,813
Licensing			7,300			—			—			7,300
Revaluation of contingent consideration			2,200			—			—			2,200
Loss from operations		$	(15,435)		$	(501)		$	(4,938)		$	(20,874)

(In thousands)					Contract			Corporate			Total
Nine Months Ended September 30, 2023		Therapeutics			Research			and Other			Company
Total revenue		$	11,210		$	14,591		$	(12,122)		$	13,679
Cost of revenue			—			14,068			(11,370)			2,698
Research and development			72,490			—			(752)			71,738
General and administrative			—			3,490			20,708			24,198
Licensing			8,955			—			—			8,955
Revaluation of contingent consideration			(600)			—			—			(600)
Loss from operations		$	(69,635)		$	(2,967)		$	(20,708)		$	(93,310)

(In thousands)					Contract			Corporate			Total
Nine Months Ended September 30, 2022		Therapeutics			Research			and Other			Company
Total revenue		$	18,469		$	12,795		$	(9,265)		$	21,999
Cost of revenue			—			11,823			(8,677)			3,146
Research and development			57,329			—			(588)			56,741
General and administrative			—			2,570			15,417			17,987
Licensing			7,300			—			—			7,300
Revaluation of contingent consideration			(2,400)			—			—			(2,400)
Loss from operations		$	(43,760)		$	(1,598)		$	(15,417)		$	(60,775)